This is a "connection" page, showing publications co-authored by Stanley Liauw and Ralph R. Weichselbaum.
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013 Feb 20; 5(173):173sr2.
Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
In Reply to Zaghloul. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):855.
Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1031-9.
The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010 Aug; 7(8):437-47.
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat. 2009 Jun; 8(3):201-6.
Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer. 2009 Apr 15; 115(8):1784-90.
Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):38-46.
Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1316-21.
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.